US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Pfizer
(NY:
PFE
)
27.50
+0.09 (+0.33%)
Official Closing Price
Updated: 4:10 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pfizer
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
99
100
Next >
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound?
↗
April 15, 2026
Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries.
Via
The Motley Fool
Topics
Regulatory Compliance
What to Look for Before Buying a Pharma Stock
↗
April 15, 2026
Start with the drug pipeline when researching pharma stocks to own.
Via
The Motley Fool
Topics
Intellectual Property
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup
↗
April 15, 2026
ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries.
Via
The Motley Fool
Topics
Regulatory Compliance
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
April 15, 2026
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...
Via
MarketMinute
Topics
Economy
Intellectual Property
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
April 14, 2026
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...
Via
MarketMinute
Topics
Bankruptcy
Earnings
Economy
Earnings Preview: What to Expect From Pfizer’s Report
April 14, 2026
Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range.
Via
Barchart.com
Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends
↗
April 14, 2026
These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance.
Via
The Motley Fool
Topics
World Trade
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
April 14, 2026
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,...
Via
Finterra
Topics
Artificial Intelligence
Death
Economy
Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
April 13, 2026
Via
PRLog
Better Buy Right Now: Johnson & Johnson Vs. Pfizer
↗
April 12, 2026
The choice is based on more than just the dividend payout.
Via
The Motley Fool
Topics
Artificial Intelligence
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe?
↗
April 10, 2026
The company has increased its payouts over the past five years despite significant challenges.
Via
The Motley Fool
Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis
April 09, 2026
In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...
Via
MarketMinute
Topics
Bonds
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
April 09, 2026
From
Pfizer Inc.
Via
Business Wire
Q4 Earnings Highs And Lows: Pfizer (NYSE:PFE) Vs The Rest Of The Branded Pharmaceuticals Stocks
April 08, 2026
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Telix Strengthens Board with Additional Director Appointments
April 08, 2026
From
Telix Pharmaceuticals Limited
Via
GlobeNewswire
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
April 08, 2026
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the...
Via
MarketMinute
OS Therapies Appoints Craig Eagle, MD as Strategic Advisor
April 08, 2026
Senior leadership roles at Guardant Health, Genentech and PfizerRegulatory, clinical and commercial expertise in therapeutics and biomarkersWill assist with osteosarcoma...
Via
Newsfile
Why Pfizer Stock Tumbled on Tuesday
↗
April 07, 2026
One analyst reiterated his pessimistic view of the pharmaceutical titan's future.
Via
The Motley Fool
Topics
Intellectual Property
Curious about the most active S&P500 stocks in today's session?
↗
April 07, 2026
Via
Chartmill
Why Is Pfizer Stock Dropping Tuesday?
↗
April 07, 2026
Pfizer Inc (NYSE:PFE) shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot trial.
Via
Benzinga
Prediction: In 5 Years, You'll Wish You Bought Pfizer Stock Today
↗
April 07, 2026
The healthcare stock looks ridiculously undervalued.
Via
The Motley Fool
Topics
Intellectual Property
AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
April 07, 2026
From
AINewsWire
Via
GlobeNewswire
Covered Call Screener Results for April 7th
April 07, 2026
Covered calls are a great strategy to add to any portfolio, and can offer enhanced yield from stock holdings, in some case, that can be a significant increase.
Via
Barchart.com
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...
Via
MarketMinute
S&P 500 Snaps Five-Week Slump with 3.4% Tech-Led Surge Amid Middle East De-escalation Hopes
April 06, 2026
The S&P 500 (NYSEARCA:SPY) concluded the week ending April 4, 2026, with a resounding 3.4% rally, marking its strongest weekly performance since late 2025. This surge effectively halted a grueling...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
ETFs
The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports
April 06, 2026
In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...
Via
MarketMinute
Topics
Economy
World Trade
2 Healthcare Stocks for Long-Term Investors and 1 We Ignore
April 06, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects...
Via
StockStory
2 Reasons to Watch PFE and 1 to Stay Cautious
April 06, 2026
Even during a down period for the markets, Pfizer has gone against the grain, climbing to $28.30. Its shares have yielded a 7.1% return over the last six mon...
Via
StockStory
The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
April 03, 2026
As of April 2026, the biotech landscape has undergone a seismic shift, moving from the "hype cycle" of early weight-loss treatments into an era of aggressive strategic consolidation. The market for...
Via
MarketMinute
Topics
Intellectual Property
Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring
April 03, 2026
WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...
Via
MarketMinute
Topics
Economy
Government
Lawsuit
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
99
100
Next >
